Thrombolytic activity of cheonggukjang kinase in recovery from brain damage in a rat cerebral embolic stroke model

被引:0
|
作者
Angella M Anthony Jalin [1 ]
Chae Kwan Lee [2 ]
Chae Yeon Lee [1 ]
A Reum Kang [1 ]
Chung Mu Park [3 ]
Jae Ho Cha [4 ]
Jeong Hwan Kim [5 ]
Soo Woong Lee [6 ]
Young Sun Song [3 ]
Jong Tae Lee [2 ]
Sung Goo Kang [1 ]
机构
[1] School of Biological Sciences,First Research Group,Inje University
[2] Institute of Environmental and Occupational Medicine & Department of Occupational and Environmental Medicine,Pusan Paik Hospital,Inje University
[3] Department of Smart Foods & Drugs,Inje University
[4] Department of Microbiology,Pusan National University
[5] Division of Applied Life Science,Gyeongsang National University
[6] Advanced Research Center for Multiple Myeloma,Department of Microbiology,Bio-Marker Research Center for Personalized Therapy,College of Medicine,Inje University
基金
新加坡国家研究基金会;
关键词
brain damage; cheonggukjang kinase; fibrin clot lysis assay; middle cerebral artery occlusion; platelet rich clot lysis assay; thrombolytic activity;
D O I
暂无
中图分类号
R285.5 [中药实验药理];
学科分类号
1008 ;
摘要
Cheonggukjang is a soybean paste made by fermenting whole cooked soybeans with Bacillus subtilis. Cheonggukjang contains a fibrinolytic enzyme that could provide clinical applications for removing blood clots. In the present study,the term "cheonggukjang kinase"(CGK) was used to refer to this fibrinolytic enzyme. The thrombolytic effects of CGK were analyzed in a rat model of cerebral embolic stroke produced by middle cerebral artery occlusion(MCAO) . Results from fibrin and platelet-rich clot lysis assays demonstrated that thrombolytic activity was greatest in CGKs,which were cultured for 40 hours. In addition,T50,the time needed to decompose 50% of the clot,did not change with plasminogen treatment,indicating that CGK was not a plasminogen activator,but was rather presumed to act as a plasmin-like protein. An intravenous infusion of CGK(1 U plasmin-like activity/100 μg CGK/kg) at 1 hour after MCAO resulted in removal of clots in a rat model of cerebral embolic stroke. CGK-treated groups exhibited a significant dose-dependent reduction in infarct volume. CGK treatment also improved functional recovery,as assessed by neurological deficit scores. Decreased infarct volume and improved functional recovery following CGK treatment was greater compared with recombinant tissue plasminogen activator(10 mg/kg) . These results suggested that CGK effectively reduced infarct volume and improved functional recovery following ischemic brain injury. CGK exhibits a number of potential clinical applications in the treatment of cerebral embolic stroke.
引用
收藏
页码:1875 / 1882
页数:8
相关论文
共 8 条
  • [1] Thrombolytic activity of cheonggukjang kinase in recovery from brain damage in a rat cerebral embolic stroke model
    Jalin, Angella M. Anthony
    Lee, Chae Kwan
    Lee, Chae Yeon
    Kang, A. Reum
    Park, Chung Mu
    Cha, Jae Ho
    Kim, Jeong Hwan
    Lee, Soo Woong
    Song, Young Sun
    Lee, Jong Tae
    Kang, Sung Goo
    NEURAL REGENERATION RESEARCH, 2010, 5 (24) : 1875 - 1882
  • [2] Effects of isosakuranetin on cerebral infarction and blood brain barrier damage from cerebral ischemia/reperfusion injury in a rat model
    Janyou, Adchara
    Moohammadaree, Aida
    Jumnongprakhon, Pichaya
    Tocharus, Chainarong
    Chokchaisiri, Ratchanaporn
    Suksamrarn, Apichart
    Tocharus, Jiraporn
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2024, 42 (02) : 1064 - 1071
  • [3] Panaxadiol Attenuates Brain Damage by Inhibiting Ferroptosis in a Rat Model of Cerebral Hemorrhage
    Zhao, Min
    Wang, Yu
    Li, Jing
    Wen, Quan
    Liu, Yue
    Zhao, Yanan
    DRUG DEVELOPMENT RESEARCH, 2025, 86 (02)
  • [4] Protein kinase C inhibition attenuates vascular ETBreceptor upregulation and decreases brain damage after cerebral ischemia in rat
    Marie Henriksson
    Emelie Stenman
    Petter Vikman
    Lars Edvinsson
    BMC Neuroscience, 8
  • [5] Cell-Free DNA-A Marker to Predict Ischemic Brain Damage in a Rat Stroke Experimental Model
    Boyko, Matthew
    Ohayon, Sharon
    Goldsmith, Tomer
    Douvdevani, Amos
    Gruenbaum, Benjamin Fredrick
    Melamed, Israel
    Knyazer, Boris
    Shapira, Yoram
    Teichberg, Vivian I.
    Elir, Adina
    Klein, Moti
    Zlotnik, Alexander
    JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY, 2011, 23 (03) : 222 - 228
  • [6] Resveratrol attenuates brain damage in a rat model of focal cerebral ischemia via up-regulation of hippocampal Bcl-2
    Li, Zhen
    Pang, Liang
    Fang, Fang
    Zhang, Gongliang
    Zhang, Jin
    Xie, Min
    Wang, Liecheng
    BRAIN RESEARCH, 2012, 1450 : 116 - 124
  • [7] BRAIN-DAMAGE FROM I-125 BRACHYTHERAPY EVALUATED BY MR IMAGING, A BLOOD-BRAIN-BARRIER TRACER, AND LIGHT AND ELECTRON-MICROSCOPY IN A RAT MODEL
    BERNSTEIN, M
    MAROTTA, T
    STEWART, P
    GLEN, J
    RESCH, L
    HENKELMAN, M
    JOURNAL OF NEUROSURGERY, 1990, 73 (04) : 585 - 593
  • [8] The selective A2A receptor antagonist SCH 58261 protects from neurological deficit, brain damage and activation of p38 MAPK in rat focal cerebral ischemia
    Melani, A
    Gianfriddo, M
    Vannucchi, MG
    Cipriani, S
    Baraldi, PG
    Giovannini, MG
    Pedata, F
    BRAIN RESEARCH, 2006, 1073 : 470 - 480